Delcath Systems, Inc.  

(Public, NASDAQ:DCTH)   Watch this stock  
Find more results for DCTH
1.36
+0.01 (0.74%)
Dec 24 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 1.32 - 1.39
52 week 1.09 - 6.72
Open 1.32
Vol / Avg. 14,073.00/78,548.00
Mkt cap 13.20M
P/E     -
Div/yield     -
EPS -2.16
Shares 9.71M
Beta 2.40
Inst. own 12%
Mar 10, 2015
Q4 2014 Delcath Systems Inc Earnings Release (Estimated) - 4:00PM EDT - Add to calendar
Nov 5, 2014
Q3 2014 Delcath Systems Inc Earnings Call - Webcast
Nov 5, 2014
Q3 2014 Delcath Systems Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '14) 2013
Net profit margin -2100.46% -3838.48%
Operating margin -2329.03% -4179.62%
EBITD margin - -4037.09%
Return on average assets -62.83% -89.75%
Return on average equity -79.72% -121.03%
Employees 37 -
CDP Score - -

Address

1301 Avenue of the Americas Fl 43
NEW YORK, NY 10019-6022
United States - Map
+1-212-4892100 (Phone)
+1-212-4892102 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Delcath Systems, Inc. (Delcath) is a development-stage, specialty pharmaceutical and medical device company, focused on oncology, initially cancers in the liver. Delcath focuses on the development and clinical study of the Delcath chemosaturation system. The Delcath chemosaturation system allows the administration of concentrated regional chemotherapy by isolating the circulatory system of the targeted organ. Once the organ is isolated, the Delcath chemosaturation system delivers doses of chemotherapeutic agents directly to the liver. The Delcath chemosaturation system involves a series of three catheter insertions, each of which is placed percutaneously through interventional radiology techniques. The procedure is minimally invasive and repeatable allowing for multiple courses of treatment with chemotherapeutic drugs. On April 13, 2011, it received Conformite Europeenne (CE) mark approval for the Delcath Hepatic CHEMOSAT Delivery System (CHEMOSAT System).

Officers and directors

Jennifer Simpson Ph.D. Interim President, Interim Chief Executive Officer
Age: 45
Bio & Compensation  - Reuters
Peter J. Graham Executive Vice President, General Counsel, Chief Compliance Officer and Global Human Resources
Age: 47
Bio & Compensation  - Reuters
John Purpura Executive Vice President - Regulatory Affairs and Quality Assurance
Age: 52
Bio & Compensation  - Reuters
Barbra C. Keck Vice President, Controller, Principal Accounting Officer, Principal Financial Officer
Age: 36
Bio & Compensation  - Reuters
Roger G. Stoll Ph.D. Executive Chairman of the Board
Age: 71
Bio & Compensation  - Reuters
Dennis H. Langer J.D. M.D. Director
Age: 62
Bio & Compensation  - Reuters
William Dodge Rueckert Director
Age: 61
Bio & Compensation  - Reuters
Marco Taglietti M.D. Director
Age: 53
Bio & Compensation  - Reuters
Harold S. Koplewicz M.D. Independent Director
Age: 61
Bio & Compensation  - Reuters
Laura A. Philips Ph.D., M.B.A. Independent Director
Age: 56
Bio & Compensation  - Reuters